Secukinumab, a monoclonal antibody specifically targeting interleukin-17A, was the first anti-interleukin-17A drug to be approved for the treatment of psoriasis by the Food and Drug Administration and the European Medicines Agency. The gene discussed is IL17A; the disease is psoriasis.